Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges.
Adjuvant osimertinib
EGFR-mutant
Early-stage NSCLC
Minimal residual disease
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
ISSN: 1556-1380
Titre abrégé: J Thorac Oncol
Pays: United States
ID NLM: 101274235
Informations de publication
Date de publication:
30 Sep 2023
30 Sep 2023
Historique:
received:
12
06
2023
revised:
21
08
2023
accepted:
27
09
2023
pubmed:
3
10
2023
medline:
3
10
2023
entrez:
2
10
2023
Statut:
aheadofprint
Résumé
Treatment with 3 years of adjuvant osimertinib is considered a new standard in patients with completely resected stage I to IIIA NSCLC harboring a common sensitizing EGFR mutation. This therapeutic approach significantly prolonged the disease-free survival and the overall survival versus placebo and revealed a significant role in preventing the occurrence of brain metastases. However, many unanswered questions remain, including the optimal duration of this therapy, whether all patients benefit from adjuvant osimertinib, and the role of adjuvant chemotherapy in this population. Indeed, there is a renewed interest in neoadjuvant strategies with targeted therapies in resectable NSCLC harboring oncogenic drivers. In light of these considerations, we discuss the past and current treatment options, and the clinical challenges that should be addressed to optimize the treatment outcomes in this patient population.
Identifiants
pubmed: 37783386
pii: S1556-0864(23)02261-X
doi: 10.1016/j.jtho.2023.09.1451
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.